Subtopic Deep Dive

← Phytochemical compounds biological activities

Quassinoids Pharmacological Mechanisms
Research Guide

What is Quassinoids Pharmacological Mechanisms?

Quassinoids pharmacological mechanisms study the molecular interactions, cytotoxicity, anti-inflammatory effects, and antimalarial activities of quassinoid compounds isolated from Simaroubaceae plants.

Quassinoids like neosergeolide and brusatol target Plasmodium falciparum, cancer cells, and inflammatory pathways. Key papers document their isolation from plants such as Picrolemma sprucei and Brucea javanica (Andrade-Neto et al., 2007, 99 citations; Cai et al., 2019, 128 citations). Over 10 listed papers cover antitumor, antimalarial, and NRF2 inhibition mechanisms, with foundational reviews citing hundreds of citations.

Curated Papers

Key Challenges

Why It Matters

Quassinoids show potent antimalarial activity against drug-resistant Plasmodium falciparum, as neosergeolide inhibited strains in vitro (Andrade-Neto et al., 2007). Brusatol inhibits NRF2 in cancer cells, enhancing chemotherapy efficacy (Cai et al., 2019). These mechanisms support development of plant-derived drugs for malaria and leukemia, addressing resistance issues (Batista et al., 2009; Lucas et al., 2010).

Key Research Challenges

Cytotoxicity Selectivity

Quassinoids exhibit high potency but poor therapeutic indices due to non-specific cytotoxicity (Cassady et al., 2004). Optimizing semisynthetic derivatives requires balancing antitumor effects with safety. Hill and Connolly (2013) note structural diversity complicates targeted modifications.

Molecular Target Identification

Exact binding sites on kinases and receptors remain unclear for most quassinoids. Brusatol's NRF2 inhibition is established, but broader mechanisms need proteomic validation (Cai et al., 2019). Pharmacokinetic profiling shows poor bioavailability limiting clinical translation.

Resistance Mechanism Elucidation

Plasmodium resistance to quassinoids like neosergeolide demands study of efflux pumps and mutations (Andrade-Neto et al., 2007). Tajuddeen and van Heerden (2019) highlight gaps in non-alkaloid antimalarials. In vivo efficacy data lags behind in vitro results.

Essential Papers

Recent Developments in the Maytansinoid Antitumor Agents

John M. Cassady, Kenneth K. Chan, Heinz G. Floss et al. · 2004 · Chemical and Pharmaceutical Bulletin · 334 citations

Maytansine and its congeners have been isolated from higher plants, mosses and from an Actinomycete, Actinosynnema pretiosum. Many of these compounds are antitumor agents of extraordinary potency, ...

Plant-Derived Antimalarial Agents: New Leads and Efficient Phytomedicines. Part II. Non-Alkaloidal Natural Products

Ronan Batista, Ademir de Jesus Silva Júnior, Alaíde de Oliveira · 2009 · Molecules · 282 citations

Malaria is still the most destructive and dangerous parasitic infection in many tropical and subtropical countries. The burden of this disease is getting worse, mainly due to the increasing resista...

Antiplasmodial natural products: an update

Nasir Tajuddeen, Fanie R. van Heerden · 2019 · Malaria Journal · 155 citations

Abstract Background Malaria remains a significant public health challenge in regions of the world where it is endemic. An unprecedented decline in malaria incidences was recorded during the last de...

Brusatol, an NRF2 inhibitor for future cancer therapeutic

Sabrina J. Cai, Yang Liu, Sue Han et al. · 2019 · Cell & Bioscience · 128 citations

In conclusion, we believe increasing evidences have shown the value of brusatol as a novel strategy for cancer treatment, which may indicate future drug development and clinical translation.

Triterpenoids

Robert A. Hill, Joseph D. Connolly · 2013 · Natural Product Reports · 111 citations

This review covers the isolation and structure determination of triterpenoids including squalene derivatives, lanostanes, holostanes, cycloartanes, cucurbitanes, dammaranes, euphanes, tirucallanes,...

Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma

David Lucas, Patrick C. Still, Lynette Bueno Pérez et al. · 2010 · Current Drug Targets · 102 citations

Hematologic malignancies account for a substantial percentage of cancers worldwide, and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challe...

Antimalarial Activity of Plant Metabolites

Wen-Hui Pan, Xinya Xu, Ni Shi et al. · 2018 · International Journal of Molecular Sciences · 101 citations

Malaria, as a major global health problem, continues to affect a large number of people each year, especially those in developing countries. Effective drug discovery is still one of the main effort...

Reading Guide

Foundational Papers

Start with Cassady et al. (2004, 334 citations) for cytotoxicity basics; Andrade-Neto et al. (2007, 99 citations) for antimalarial evidence; Hill and Connolly (2013, 111 citations) for structural mechanisms.

Recent Advances

Cai et al. (2019, 128 citations) on brusatol-NRF2; Tajuddeen and van Heerden (2019, 155 citations) updating antiplasmodial quassinoids; Zhuo et al. (2015, 101 citations) on ailanthone apoptosis.

Core Methods

In vitro Plasmodium inhibition assays (Andrade-Neto et al., 2007); cell cycle/apoptosis analysis (Zhuo et al., 2015); NRF2 pathway inhibition (Cai et al., 2019).

How PapersFlow Helps You Research Quassinoids Pharmacological Mechanisms

Discover & Search

Research Agent uses searchPapers and exaSearch to find quassinoid mechanism papers, starting with 'neosergeolide Plasmodium inhibition' yielding Andrade-Neto et al. (2007). citationGraph reveals connections to Batista et al. (2009, 282 citations), and findSimilarPapers expands to brusatol studies like Cai et al. (2019).

Analyze & Verify

Analysis Agent applies readPaperContent to extract IC50 values from Andrade-Neto et al. (2007), then runPythonAnalysis with pandas to compare potencies across quassinoids. verifyResponse (CoVe) and GRADE grading confirm NRF2 inhibition claims in Cai et al. (2019) against contradictions in triterpenoid reviews.

Synthesize & Write

Synthesis Agent detects gaps in quassinoid selectivity using gap detection on Hill and Connolly (2013), flagging underexplored semisynthetics. Writing Agent employs latexEditText and latexSyncCitations to draft mechanism reviews citing 10+ papers, with latexCompile for publication-ready output and exportMermaid for signaling pathway diagrams.

Use Cases

"Compare IC50 values of quassinoids against Plasmodium strains from Amazonian plants."

Research Agent → searchPapers → Analysis Agent → readPaperContent (Andrade-Neto 2007) → runPythonAnalysis (pandas plot IC50 distributions) → matplotlib dose-response curves output.

"Draft LaTeX review on brusatol NRF2 inhibition mechanisms."

Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Cai 2019 et al.) → latexCompile → PDF with pathway Mermaid diagram.

"Find GitHub code for quassinoid structure-activity analysis."

Research Agent → citationGraph (Hill 2013) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → QSAR modeling scripts for neosergeolide derivatives.

Automated Workflows

Deep Research workflow scans 50+ quassinoid papers via searchPapers chains, producing structured reports on antimalarial mechanisms with GRADE scores. DeepScan applies 7-step analysis to verify cytotoxicity data from Cassady et al. (2004), including CoVe checkpoints. Theorizer generates hypotheses on quassinoid-NRF2 interactions from Cai et al. (2019) and related citations.

Try Doxa for Quassinoids Pharmacological Mechanisms Research

Frequently Asked Questions

What defines quassinoids pharmacological mechanisms?

Quassinoids are degraded triterpenoids from Simaroubaceae with mechanisms including Plasmodium inhibition, NRF2 modulation, and cytotoxicity (Hill and Connolly, 2013).

What are key methods for studying quassinoid activity?

In vitro assays measure IC50 against Plasmodium (Andrade-Neto et al., 2007); cell cycle arrest and apoptosis assays assess anticancer effects (Zhuo et al., 2015).

Which papers establish quassinoid antimalarial mechanisms?

Andrade-Neto et al. (2007, 99 citations) shows neosergeolide potency; Batista et al. (2009, 282 citations) reviews non-alkaloidal leads.

What open problems exist in quassinoid research?

Challenges include selectivity over cytotoxicity, target identification beyond NRF2, and in vivo pharmacokinetics (Cai et al., 2019; Cassady et al., 2004).